SOHO 2023 | The challenge of persistent MRD in T-ALL & novel approaches being explored
Caner Saygin
• 7 Sep 2023
Caner Saygin, MD, University of Chicago, Chicago, IL discusses the challenges associated with persistent measurable residual disease (MRD) in patients with T-cell acute lymphoblastic leukemia (T-ALL), highlighting the lack of immunotherapeutic options available for patients who relapse after frontline therapy and the importance of enrolling patients in clinical trials. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
